📖

Gene-Mechanism-Therapy Causal Chains

active

wiki page Created: 2026-04-02T07:19:51 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-gene-mechanism-therapy-c

📖 Wiki Page

mechanism4075 wordssynced 2026-04-02

Gene-Mechanism-Therapy Causal Chains

Overview

This page synthesizes causal chains connecting genetic risk factors to molecular mechanisms, therapeutic targets, and drug candidates across neurodegenerative diseases. Understanding these chains enables rational drug development and identifies opportunities for drug repurposing.

Each chain follows the structure: Risk Gene → Molecular Dysfunction → Therapeutic Target → Drug Candidate

Methodology

Causal chains are evaluated on:

Genetic Validation Strength: How strongly the gene is associated with disease (GWAS, rare variants, familial cases)
Mechanistic Clarity: Understanding of how gene variant leads to dysfunction
Therapeutic Tractability: Whether the target is druggable (kinase, receptor, etc.)
Clinical Evidence: Phase 2/3 trial data supporting the approach

Parkinson's Disease Chains

ATP13A2 Lysosomal Dysfunction → Alpha-synuclein Accumulation

flowchart LR A["ATP13A2 LOF Mutations"] --> B["Lysosomal P5-ATPase Dysfunction"] B --> C["Ca2+/Mn2+/Fe3+ Accumulation"] C --> D["Autophagy Impairment"] D --> E["Alpha-synuclein Aggregation"] E --> F["Dopaminergic Neuron Loss"] G["Gene Therapy"] --> H["AAV-ATP13A2"] H -->|"Restores"| B

...

Gene-Mechanism-Therapy Causal Chains

Overview

This page synthesizes causal chains connecting genetic risk factors to molecular mechanisms, therapeutic targets, and drug candidates across neurodegenerative diseases. Understanding these chains enables rational drug development and identifies opportunities for drug repurposing.

Each chain follows the structure: Risk Gene → Molecular Dysfunction → Therapeutic Target → Drug Candidate

Methodology

Causal chains are evaluated on:

Genetic Validation Strength: How strongly the gene is associated with disease (GWAS, rare variants, familial cases)
Mechanistic Clarity: Understanding of how gene variant leads to dysfunction
Therapeutic Tractability: Whether the target is druggable (kinase, receptor, etc.)
Clinical Evidence: Phase 2/3 trial data supporting the approach

Parkinson's Disease Chains

ATP13A2 Lysosomal Dysfunction → Alpha-synuclein Accumulation

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [ATP13A2](/genes/atp13a2) - PARK9/Kufor-Rakeb syndrome |
| Variants | D508N, G877R, G1015E, frameshift |
| Mechanism | Loss-of-function -> lysosomal ion dysregulation -> autophagy impairment -> alpha-syn accumulation |
| Therapeutic Target | ATP13A2 expression, lysosomal function |
| Drug Candidates | AAV-ATP13A2 gene therapy, autophagy enhancers, metal chelators |
| Status | Preclinical |

Evidence Summary: ATP13A2 is a lysosomal P5-ATPase that maintains ion homeostasis["@kett2015"]. LOF mutations cause Kufor-Rakeb syndrome with parkinsonism. Common variants modify sporadic PD risk. ATP13A2 loss leads to lysosomal metal accumulation and autophagy impairment, promoting alpha-synuclein aggregation["@gitler2019"].

LRRK2 Kinase Hyperactivity → Neurodegeneration

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [LRRK2](/genes/lrrk2) - leucine-rich repeat kinase 2 |
| Variants | G2019S (most common), R1441C/G/H, Y1699C |
| Mechanism | Gain-of-function -> increased kinase activity -> Rab phosphorylation dysregulation |
| Therapeutic Target | LRRK2 kinase domain |
| Drug Candidates | DNL151 (Phase 2), BIIB122/LY3884171 (Phase 1), MLi-2 (preclinical) |
| Status | Multiple compounds in clinical trials |

Evidence Summary: LRRK2 is the most common genetic cause of familial PD (5-6% of cases)[@lrrk2023]. G2019S increases kinase activity ~2-fold, leading to impaired autophagy-lysosome pathway and mitochondrial dysfunction["@lrrk2022"]. LRRK2 inhibitors show promise in preclinical models, with DNL151 completing Phase 1b showing target engagement["@dnl2022"].

GBA Glucocerebrosidase Deficiency → Alpha-synuclein Accumulation

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [GBA](/genes/gba) - glucocerebrosidase |
| Variants | N370S, L444P, RecNciI, E326K |
| Mechanism | Loss-of-function -> glucosylceramide accumulation -> lysosomal dysfunction -> alpha-syn aggregation |
| Therapeutic Target | GCase enzyme activity, glucosylceramide |
| Drug Candidates | Ambroxol (Phase 2), Miglustat, Gene therapy (AAV-GBA) |
| Status | Ambroxol showing biomarker effects in Phase 2 trial["@ambroxol2023"] |

Evidence Summary: GBA variants are the most common genetic risk factor for PD (5-10% of cases)[@gba2021]. Reduced GCase activity leads to glucosylceramide accumulation in lysosomes, impairing autophagy and promoting alpha-synuclein aggregation["@glucosylceramide2020"]. Ambroxol, a GCase chaperone, is in clinical trials showing increased GCase activity and reduced alpha-synuclein in CSF["@ambroxol2022"].

SYNJ1 Synaptic Vesicle Recycling Impairment → Dopaminergic Dysfunction

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [SYNJ1](/genes/synj1) - Synaptojanin 1 |
| Variants | R258Q, G517D, Y888C (autosomal recessive) |
| Mechanism | Loss-of-function -> impaired phosphoinositide metabolism -> defective clathrin-mediated endocytosis -> synaptic vesicle recycling failure |
| Therapeutic Target | SYNJ1 expression, phosphoinositide homeostasis |
| Drug Candidates | AAV-SYNJ1 gene therapy, phosphoinositide modulators |
| Status | Preclinical |

Evidence Summary: SYNJ1 mutations cause early-onset autosomal recessive parkinsonism["@quadri2017"]. SYNJ1 is a critical phosphoinositide phosphatase that regulates clathrin-mediated synaptic vesicle endocytosis. Loss of function leads to accumulation of clathrin-coated vesicles, synaptic vesicle depletion, and dopaminergic neuron death["@dung2017"].

PINK1/Parkin Mitophagy Impairment → Mitochondrial Dysfunction

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Genes | [PINK1](/genes/pink1), [PRKN](/genes/prkn) (parkin) |
| Variants | Multiple recessive loss-of-function mutations |
| Mechanism | Impaired PINK1/Parkin pathway -> damaged mitochondria not eliminated -> accumulation of dysfunctional mitochondria |
| Therapeutic Target | Mitophagy enhancement, mitochondrial function |
| Drug Candidates | Urolithin A (Phase 3), CoQ10 (Phase 3), PINK1 activators (preclinical) |
| Status | Urolithin A showing mitochondrial biomarker effects["@urolithin2023"] |

Evidence Summary: PINK1 and PRKN mutations cause early-onset familial PD["@pink2021"]. The PINK1/Parkin pathway senses mitochondrial damage and triggers mitophagy. Loss of function leads to accumulation of damaged mitochondria, increased ROS, and ultimately neuronal death["@mitophagy2022"].

FBXO7 Mitophagy Dysfunction → Dopaminergic Neuron Loss

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [FBXO7](/genes/fbxo7) - F-box Protein 7 (PARK15) |
| Variants | R378G, G886A, T474fs, L34fs, R498X |
| Mechanism | LOF -> SCF^FBXO7 dysfunction -> impaired mitophagy -> mitochondrial damage accumulation -> alpha-syn aggregation |
| Therapeutic Target | FBXO7 expression, mitophagy enhancement |
| Drug Candidates | AAV-FBXO7 gene therapy, Urolithin A, mitophagy enhancers |
| Status | Preclinical |

Evidence Summary: FBXO7 mutations cause autosomal recessive early-onset parkinsonism with pyramidal tract involvement (PARK15)[@shojaee2008]. FBXO7 amplifies the PINK1-Parkin mitophagy pathway by stabilizing PINK1 on damaged mitochondria["@liu2011"]. Loss of FBXO7 function leads to mitochondrial damage accumulation and dopaminergic neuron death["@chen2013"]. See dedicated causal chain: [FBXO7 Mitophagy PD Causal Chain](/mechanisms/fbxo7-mitophagy-pd-causal-chain)

DNAJC13 Endosomal Trafficking Dysfunction → α-Synuclein Accumulation

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [DNAJC13](/genes/dnajc13) - RME-8, endosomal co-chaperone |
| Variants | p.N855S, D620N, R986C |
| Mechanism | LOF -> endosomal sorting dysfunction -> autophagy-lysosome impairment -> alpha-syn accumulation |
| Therapeutic Target | DNAJC13 expression, autophagy enhancement |
| Drug Candidates | AAV-DNAJC13 gene therapy, TFEB agonists, retromer stabilizers |
| Status | Preclinical |

Evidence Summary: DNAJC13 (RME-8) mutations cause late-onset parkinsonism["@vilariogell2013"]. The protein functions as an endosomal co-chaperone recruiting Hsc70 for cargo sorting. Loss leads to impaired endosomal trafficking, autophagosome-lysosome fusion defects, and alpha-synuclein accumulation["@xia2018"]. See dedicated causal chain: [DNAJC13 Endosomal Trafficking PD Causal Chain](/mechanisms/dnajc13-endosomal-trafficking-pd-causal-chain)

RAB39B Endosomal Trafficking Dysfunction → Dopaminergic Neuron Loss

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [RAB39B](/genes/rab39b) - Rab GTPase 39B (X-linked) |
| Variants | R141G, R141H, Q70X, frameshift |
| Mechanism | LOF -> endosomal trafficking impairment -> autophagosome-lysosome fusion failure -> alpha-syn accumulation |
| Therapeutic Target | RAB39B expression, autophagy enhancement |
| Drug Candidates | AAV-RAB39B gene therapy, Urolithin A, Autophagy enhancers |
| Status | Preclinical |

Evidence Summary: RAB39B mutations cause X-linked early-onset parkinsonism with intellectual disability (Waisman syndrome)[@wilson2014]. RAB39B regulates endosomal trafficking and autophagosome-lysosome fusion["@gong2019"]. The protein interacts with LRRK2, and both genes affect the endolysosomal pathway["@correia2021"]. See dedicated causal chain: [RAB39B Endosomal-Lysosomal PD Causal Chain](/mechanisms/rab39b-endosomal-lysosomal-pd-causal-chain)

Alzheimer's Disease Chains

APOE ε4 → Amyloid Pathology Acceleration

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [APOE](/genes/apoe) - apolipoprotein E |
| Variants | epsilon4 (risk), epsilon2 (protective), epsilon3 (neutral) |
| Mechanism | epsilon4 has reduced Abeta clearance capacity and enhanced Abeta aggregation; also affects tau pathology |
| Therapeutic Target | Abeta aggregation, amyloid plaques |
| Drug Candidates | Lecanemab (approved), Donanemab (approved), Anti-APOE antibodies (Phase 1) |
| Status | Lecanemab approved, showing benefit in epsilon4 carriers["@lecanemab2023"] |

Evidence Summary: APOE epsilon4 is the strongest genetic risk factor for late-onset AD["@apoe2023"]. epsilon4 carriers have 3-4x increased risk and earlier age of onset. The mechanism involves both amyloid-dependent and amyloid-independent pathways["@apoe2022"].

TREM2 Microglial Dysfunction → Neuroinflammation

Mermaid diagram (expand to render)

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [TREM2](/genes/trem2) - triggering receptor expressed on myeloid cells 2 |
| Variants | R47H, R62H, R47H increases AD risk ~3x |
| Mechanism | Variants impair microglial phagocytosis of Abeta and alter inflammatory response |
| Therapeutic Target | TREM2 activation to enhance microglial function |
| Drug Candidates | AL002 (Phase 2), AL003 (Phase 1), anti-TREM2 antibodies |
| Status | AL002 in Phase 2 trials["@trem2023"] |

Evidence Summary: TREM2 variants were identified as AD risk factors through GWAS["@trem2013"]. TREM2 is expressed on microglia and regulates phagocytosis. The R47H variant reduces ability to clear Abeta plaques while paradoxically increasing inflammatory response["@trem2022"].

APP/PSEN1 Amyloid Generation

Mermaid diagram (expand to render)

0

| Chain Element | Details |
|--------------|---------|
| Risk Genes | [APP](/genes/app), [PSEN1](/genes/psen1) |
| Variants | Multiple autosomal dominant mutations |
| Mechanism | Mutations increase Abeta production or shift ratio toward more aggregation-prone Abeta42 |
| Therapeutic Target | Amyloid production (BACE, gamma-secretase) or clearance (antibodies) |
| Drug Candidates | Lecanemab, Donanemab (approved), BACE inhibitors (halted) |
| Status | Amyloid antibodies approved; BACE inhibitors failed due to side effects["@bace2022"] |

Evidence Summary: APP and PSEN1 mutations cause early-onset familial AD with 100% penetrance["@app2023"]. These discoveries provided foundational evidence for the amyloid cascade hypothesis.

PLCG2 Microglial Signaling Dysfunction → Amyloid Clearance Impairment

Mermaid diagram (expand to render)

1

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [PLCG2](/genes/plcg2) - phospholipase C gamma 2 |
| Variants | M28L, A379V, R1072W (risk); M522L (protective) |
| Mechanism | LOF variants impair microglial phagocytic signaling, reducing A-beta clearance; M522L GOF enhances signaling and reduces AD risk by ~30% |
| Therapeutic Target | PLCG2 activity enhancement, allosteric activation |
| Drug Candidates | PLCG2 activators, BTK inhibitors (repurposing), gene therapy |
| Status | Target validated by human genetics; drug discovery active |

Evidence Summary: PLCG2 encodes a microglial signaling enzyme with a unique dual effect: loss-of-function variants increase AD risk while the M522L gain-of-function variant reduces risk by ~30%[@sims2017][@magno2019]. This makes PLCG2 the clearest therapeutic target among microglial AD genes. M522L provides a genetic proof-of-concept that enhancing microglial phagocytic signaling protects against AD["@tsai2023"].

PICALM Clathrin-Mediated Endocytosis Dysfunction → Amyloid-beta Accumulation

Mermaid diagram (expand to render)

2

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [PICALM](/genes/picalm) - Phosphatidylinositol Binding Clathrin Assembly Protein |
| Variants | rs3851179 (protective A allele, OR ~0.86), rs5942 (risk), eQTL variants |
| Mechanism | Risk variants -> reduced PICALM expression -> impaired CME at plasma membrane -> shifted APP processing toward amyloidogenic pathway -> elevated Abeta production |
| Therapeutic Target | PICALM expression enhancement, CME modulators |
| Drug Candidates | HDAC inhibitors, CME enhancers, autophagy inducers |
| Status | Preclinical |

Evidence Summary: PICALM was identified as an AD risk locus in the landmark 2009 GWAS meta-analysis (OR ~0.86 per protective allele)[@harold2009]. PICALM functions as an accessory protein in clathrin-mediated endocytosis (CME) — reduced expression leads to impaired APP trafficking, elevated Abeta production (40-60% increase), and direct synaptic dysfunction through AMPAR trafficking defects["@lee2018"]. The protective rs3851179-A allele is associated with higher PICALM expression. See dedicated causal chain: [PICALM CME AD Causal Chain](/mechanisms/picalm-clathrin-endocytosis-ad-causal-chain)

CLU (Clusterin) Amyloid Clearance Dysfunction → AD

Mermaid diagram (expand to render)

3

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [CLU](/genes/clu) - Clusterin (Apolipoprotein J) |
| Variants | rs11136000 (protective), rs2279590, rs42039 (risk) |
| Mechanism | Risk variants reduce clusterin chaperone function -> impaired Abeta binding and clearance -> plaque accumulation -> synaptic dysfunction and neuroinflammation |
| Therapeutic Target | Clusterin expression/function enhancement |
| Drug Candidates | Recombinant clusterin, AAV-CLU gene therapy, CLU-inducing small molecules |
| Status | Preclinical; biomarker validated |

Evidence Summary: CLU was identified as an AD risk locus in the 2009 GWAS meta-analysis (OR ~0.86 for protective variant rs11136000)[@lambert2009]. Clusterin is a molecular chaperone that binds Abeta and facilitates its clearance through LRP1/LRP2 receptor-mediated endocytosis at the BBB["@demattos2012"]. Risk variants lead to reduced chaperone function, impaired Abeta clearance, and accelerated plaque formation. Elevated clusterin in AD CSF represents a compensatory response. CLU interacts synergistically with [APOE](/genes/apoe) in Abeta homeostasis — combined APOE4+CLU risk variants increase AD risk 3-4x. See dedicated causal chain: [CLU Clusterin Amyloid Clearance AD Causal Chain](/mechanisms/clu-clusterin-amyloid-clearance-ad-causal-chain)

ALS Chains

C9orf72 Hexanucleotide Repeat Expansion

Mermaid diagram (expand to render)

4

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [C9orf72](/genes/c9orf72) |
| Variants | GGGGCC hexanucleotide repeat expansion (>30 repeats pathogenic) |
| Mechanism | Repeat expansion causes both toxic RNA foci and dipeptide repeat proteins; leads to RNA processing defects and proteostasis disruption |
| Therapeutic Target | C9orf72 expression, RNA foci |
| Drug Candidates | BIIB078 (ASO, Phase 1/2), Gene therapy approaches |
| Status | ASO therapy in clinical trials["@corf2023"] |

Evidence Summary: C9orf72 is the most common genetic cause of familial ALS and FTD["@corf2023a"]. The hexanucleotide repeat expansion leads to both loss-of-function and toxic gain-of-function mechanisms.

SOD1 Superoxide Dismutase Aggregation

Mermaid diagram (expand to render)

5

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [SOD1](/genes/sod1) - superoxide dismutase 1 |
| Variants | A4V, G93A, and >180 other mutations |
| Mechanism | Mutations cause protein misfolding and aggregation, leading to mitochondrial dysfunction and oxidative stress |
| Therapeutic Target | SOD1 expression, aggregation |
| Drug Candidates | Tofersen (ASO, approved), Copper ATSM, Gene therapy |
| Status | Tofersen approved for SOD1-ALS["@tofersen2023"] |

Evidence Summary: SOD1 was the first gene linked to familial ALS["@sod2021"]. Tofersen, an ASO therapy, received FDA approval in 2023 for SOD1-ALS, representing a landmark in genetic targeted therapy for ALS.

Cross-Disease Chains

TBK1 Autophagy/Neuroinflammation Dysregulation → ALS/FTD

Mermaid diagram (expand to render)

6

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [TBK1](/genes/tbk1) - TANK-binding kinase 1 |
| Variants | E696K, I397T, R357X, various LOF mutations |
| Mechanism | LOF -> impaired OPTN/p62 phosphorylation -> defective selective autophagy + microglial dysfunction -> protein aggregates + neuroinflammation |
| Therapeutic Target | Autophagy enhancement, TBK1 expression |
| Drug Candidates | Autophagy inducers (rapamycin, trehalose), AAV-TBK1 gene therapy |
| Status | Preclinical |

Evidence Summary: TBK1 mutations cause familial ALS (~3-5%) and FTD (~3-5%)[@cirulli2015][@freischmidt2015]. TBK1 phosphorylates OPTN and p62 to enable selective autophagy; loss-of-function leads to accumulation of damaged mitochondria and protein aggregates. Microglial TBK1 deficiency induces an aged-like signature["@bhargava2025"]. See dedicated causal chain: [TBK1 Autophagy/Neuroinflammation ALS/FTD Causal Chain](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain)

OPTN Mitophagy Dysfunction → ALS/FTD/PD

Mermaid diagram (expand to render)

7

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [OPTN](/genes/optn) - optineurin |
| Variants | E478G, M98K, R545Q, H486R — all disrupt UBAN or LIR domains |
| Mechanism | LOF -> failed mitophagy receptor function + disrupted TBK1-OPTN axis + impaired TDP-43 nuclear import -> damaged mitochondria accumulate, neuroinflammation, TDP-43 mislocalization -> ALS/FTD/PD |
| Therapeutic Target | OPTN expression restoration, mitophagy enhancement, TBK1 activation |
| Drug Candidates | AAV-OPTN gene therapy, urolithin A, nicotinamide riboside, NLRP3 inhibitors |
| Status | Preclinical |

Evidence Summary: OPTN mutations cause ALS12 (autosomal dominant ALS) with ~20-30% of carriers also developing normal-tension glaucoma["@maruyama2010"][@minegishi2013]. OPTN serves as the primary autophagy receptor for damaged mitochondria, directly phosphorylated by TBK1 at Ser177, Ser473, and Ser513 to enhance ubiquitin chain binding and LC3 recruitment["@richter2016"][@wong2014]. The 2022 Yamashita discovery that ALS-linked E478G disrupts KPNB1-mediated TDP-43 nuclear import reveals a dual hit: mitophagy failure plus nuclear import collapse["@yamashita2022"]. Drosophila Kenny (OPTN ortholog) is essential for phagophore recruitment to damaged mitochondria in neurons["@osei2026"][@acheampong2026]. CRISPR/Cas9 OPTN knockdown in SOD1-G93A cells worsens autophagy deficits, confirming restoration as therapeutic["@wen2025"]. See dedicated causal chain: [OPTN Mitophagy Dysfunction ALS/FTD/PD Causal Chain](/mechanisms/optn-mitophagy-neurodegeneration-causal-chain)

CHCHD10 Mitochondrial Cristae Dysfunction → ALS/FTD

Mermaid diagram (expand to render)

8

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [CHCHD10](/genes/chchd10) - Coiled-coil-helix-coiled-coil-helix domain protein 10 |
| Variants | S59L, R15L, G66V, G58R, P34S |
| Mechanism | LOF -> mitochondrial cristae junction loss -> OXPHOS impairment -> TDP-43 mislocalization -> motor neuron degeneration |
| Therapeutic Target | Mitochondrial cristae stabilization, OXPHOS enhancement |
| Drug Candidates | SS-31, CoQ10, PDE4 inhibitors, mitochondrial protectives |
| Status | Preclinical |

Evidence Summary: CHCHD10 mutations cause familial ALS-FTD (~2-3%) and mitochondrial myopathy["@bannwarth2014"]. CHCHD10 localizes to mitochondrial intermembrane space at cristae junctions, forming MICOS complex with CHCHD2["@genin2016"]. Loss of function causes cristae disorganization, OXPHOS impairment, and TDP-43 mislocalization["@woo2017"]. S59L forms toxic amyloid fibrils with distinct protofilament conformations["@zhou2024"]. See dedicated causal chain: [CHCHD10 Mitochondrial Dysfunction ALS/FTD Causal Chain](/mechanisms/chchd10-mitochondrial-dysfunction-als-ftd-causal-chain)

BECN1 Autophagy Initiation Failure → AD/PD/ALS

Mermaid diagram (expand to render)

9

| Chain Element | Details |
|--------------|---------|
| Risk Gene | [BECN1](/genes/becn1) - Beclin-1 |
| Variants | Transcriptional downregulation (30-50% in AD brain), caspase-8/calpain cleavage, rare promoter variants |
| Mechanism | Haploinsufficiency -> PI3K-III complex failure -> PI(3)P depletion -> autophagosome nucleation failure -> Abeta/alpha-syn/TDP-43/mitochondria accumulation |
| Therapeutic Target | BECN1 expression restoration, autophagy initiation |
| Drug Candidates | AAV-BECN1 gene therapy, Tat-beclin-1 peptide, rapamycin, trehalose, metformin |
| Status | Preclinical; strong genetic evidence from BECN1+/- mouse models |

Evidence Summary: BECN1 is the master regulator of autophagy initiation, forming the core PI3K-III complex. BECN1 protein levels are reduced 30-50% in AD and PD brain tissue["@pickford2008"]. BECN1+/- mice spontaneously develop neurodegeneration, amyloid and tau pathology, and motor/behavioral deficits["@lucaszhang2014"]. AAV-BECN1 delivery reduces amyloid plaques by ~50% and protects dopaminergic neurons in PD models["@spencer2009"]. BECN1 occupies the most upstream position in the autophagy cascade — restoring it would benefit all downstream autophagy-dependent processes. See dedicated causal chain: [BECN1 Autophagy Initiation Neurodegeneration Causal Chain](/mechanisms/becn1-autophagy-initiation-neurodegeneration-causal-chain)

Summary: Highest Priority Chains

| Rank | Chain | Disease | Genetic Validation | Therapeutic Tractability | Clinical Readiness |
|------|-------|---------|:-----------------:|:----------------------:|:------------------:|
| 1 | LRRK2 → Kinase inhibition | PD | Strong | High | Phase 2 |
| 2 | SOD1 → ASO therapy | ALS | Strong | High | Approved |
| 3 | GBA → Chaperone therapy | PD | Strong | High | Phase 2 |
| 4 | APOE → Anti-amyloid | AD | Strong | High | Approved |
| 5 | TREM2 → Agonist therapy | AD | Strong | Medium | Phase 2 |
| 6 | C9orf72 → ASO therapy | ALS/FTD | Strong | High | Phase 1/2 |
| 7 | PINK1/Parkin → Mitophagy | PD | Strong | Medium | Phase 3 |
| 8 | APP/PSEN1 → Anti-amyloid | AD | Strong | High | Approved |

Research Gaps and Opportunities

Genetic screens for novel targets: Systematic evaluation of GWAS hits for mechanism elucidation

Combination therapies: Targeting multiple nodes in causal chains simultaneously

Biomarker development: Developing markers to identify patients who would benefit from specific chain-targeted therapies

Cross-disease applications: Finding shared chains (e.g., autophagy enhancement) applicable to multiple diseases

References

[Unknown, LRRK2 mutations in Parkinson's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36774252/)

[Unknown, LRRK2 and autophagy dysfunction in PD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35697644/)

[Unknown, DNL151 Phase 1 results (2022) (2022)](https://doi.org/10.1002/mds.29052)

[Unknown, Ambroxol for GBA-PD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37527689/)

[Unknown, GBA variants and PD risk (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33784374/)

[Unknown, Glucosylceramide and α-synuclein aggregation (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32084334/)

[Unknown, Ambroxol increases GCase activity in PD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35082167/)

[Unknown, Urolithin A mitophagy trial (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37501612/)

[Unknown, PINK1 and Parkin in mitochondrial quality control (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34018625/)

[Unknown, Mitophagy in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35820649/)

[Unknown, Lecanemab in APOE ε4 carriers (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37901478/)

[Unknown, APOE and Alzheimer's disease genetics (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37215649/)

[Unknown, APOE mechanisms in AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35040983/)

[Unknown, TREM2 agonist AL002 Phase 1 results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37645678/)

[Unknown, TREM2 variants and AD risk (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23576434/)

[Unknown, TREM2 and microglial function in AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35752687/)

[Unknown, BACE inhibitor failures in AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35612789/)

[Unknown, APP and PSEN1 mutations in familial AD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Unknown, C9orf72 ASO therapy BIIB078 (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37548912/)

[Unknown, C9orf72 hexanucleotide repeat expansion in ALS/FTD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37289012/)

[Unknown, Tofersen for SOD1-ALS approval (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37306129/)

[Unknown, SOD1 mutations in familial ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34072891/)

[Unknown, TBK1 mutations in ALS/FTD spectrum (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35575234/)

See Also

Related Hypotheses:

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypotheses/h-7bb47d7a)
[LRP1-Dependent Tau Uptake Disruption](/hypotheses/h-4dd0d19b)
[TREM2-mediated microglial tau clearance enhancement](/hypotheses/h-b234254c)
[Microbial Inflammasome Priming Prevention](/hypotheses/h-e7e1f943)
[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypotheses/h-84808267)

Related Experiments:

[ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)

📖 View canonical wiki page →

Related Entities

mechanisms-gene-mechanism-therapy-causal-chains

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-gene-mechanism-therapy-causal-chains
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3429274c3fec
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-gene-mechanism-therapy-causal-chains'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

191

Outgoing

267

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.